# GLP-1 Receptor Agonists

## Renal Effects and Outcomes

### Major Clinical Evidence

**FLOW Trial (2024):** Halted early due to compelling evidence — semaglutide 1.0 mg weekly significantly reduced kidney failure, sustained eGFR reduction ≥50%, and cardiovascular death in patients with T2D and CKD.

The Badve et al. meta-analysis of randomized trials found that GLP-1 receptor agonists reduced clinically important kidney and cardiovascular outcomes in the studied populations. Outcome definitions, trial populations, and pooled effect measures matter; the results do not establish identical benefit for every agent or every kidney disease. [PubMed source](https://pubmed.ncbi.nlm.nih.gov/39608381/)

### Renal Protection Mechanisms

1.  **Restoration of Tubuloglomerular Feedback:** GLP-1RAs induce diuresis and natriuresis by direct inhibition of NHE3 on proximal tubular cells
2.  **Glomerular Hemodynamics:** Enhanced sodium delivery to macula densa restores normal TGF and suppresses RAAS overactivation
3.  **Anti-inflammatory Effects:** GLP-1 receptors in kidneys dampen RAGE-induced inflammation

### Clinical Outcomes Data

- **Primary Prevention:** 21% reduction in composite renal outcomes
- **Acute Kidney Disease:** 43% mortality reduction (aHR 0.57) in T2D patients with AKD
- **Transplant Recipients:** Significantly lower likelihood of sustaining 40% eGFR reduction, with better graft and patient survival

### Diuretic Effects and Natriuresis

- GLP-1 promotes natriuresis by inhibiting NHE3: 40–60% increases in sodium excretion and 60% increases in calcium excretion during volume loading
- GLP-1 receptors in pelvic wall activate afferent renal nerves (110% increase in nerve activity)

## Cardiovascular Effects and BNP Modulation

### BNP Modulation

GLP-1RAs significantly decrease NT-proBNP (−0.14 SD; 95% CI −0.27 to −0.01; p = 0.03), independent of baseline age, body weight, and metabolic control.

### Cardiovascular Outcomes Trial Results

| Trial | Agent | Population | MACE HR (95% CI) | ARR | NNT (3 yr) |
|----|----|----|----|----|----|
| **LEADER** | Liraglutide 1.8 mg | T2DM + CVD/risk | 0.87 (0.78–0.97) | 2.3% | 43 |
| **SUSTAIN-6** | Semaglutide SC | T2DM + CVD/risk | 0.74 (0.58–0.95) | 2.9% | 34 |
| **REWIND** | Dulaglutide 1.5 mg | T2DM (31% 1° prev.) | 0.88 (0.79–0.99) | 1.2% | 83 |
| **HARMONY** | Albiglutide | T2DM + CVD | 0.78 (0.68–0.90) | 2.1% | 48 |
| **AMPLITUDE-O** | Efpeglenatide | T2DM + CVD/risk | 0.73 (0.58–0.92) | 3.4% | 29 |
| **SELECT** | Semaglutide 2.4 mg | Obesity + CVD, no DM | 0.80 (0.72–0.90) | 1.5% | 67 |

### Individual MACE Components

- **CV Death:** 13% relative reduction (HR 0.87; 95% CI 0.81–0.94) — NNT 83–143
- **MI:** 9% relative reduction (HR 0.91; 95% CI 0.84–0.99) — NNT 125–250
- **Stroke:** 16% relative reduction (HR 0.84; 95% CI 0.76–0.93) — unique benefit vs. SGLT2i — NNT 111–200
- **HF Hospitalization:** 11% reduction (HR 0.89; 95% CI 0.82–0.98) — NNT 125–250

Clinical Pearl

GLP-1 RAs provide a unique **stroke reduction benefit** (16%) that SGLT2 inhibitors do not. For patients with high stroke risk, GLP-1 RAs should be prioritized in the treatment algorithm.

## Anti-Inflammatory Properties

### Molecular Mechanisms

- **NF-kB Pathway Inhibition:** Block NF-kB activation and decrease TNF-alpha, IL-6, and IL-1beta
- **Central Anti-Inflammatory Action:** CNS GLP-1R activation required for systemic effects
- **Macrophage Polarization:** Shift toward M2 anti-inflammatory phenotype with 35% TNF-alpha reduction after LPS challenge

### Tissue-Specific Effects

- **Cardiovascular:** Reduced atherosclerotic plaque inflammation
- **Hepatic:** Improved NASH through AMPK/mTOR autophagy pathway
- **Renal:** Protection against diabetic nephropathy via cAMP-PKA pathway
- **Neurological:** Neuroprotection in neurodegeneration and stroke models

## Protein Requirements During GLP-1 Therapy

Muscle Mass Warning

In some studies, **40–60% of total weight lost** was attributed to muscle mass rather than fat. Proactive protein optimization is essential during GLP-1 therapy.

### Evidence-Based Protein Targets

| Category | Target (g/kg/day) | Context |
|----|----|----|
| Minimum Threshold | 1.2 | Muscle preservation baseline |
| **Optimal Range** | **1.6–2.0** | During active weight loss |
| High-Risk (elderly, rapid loss) | Up to 2.4 | Older adults or rapid weight loss |

### Key Evidence

- Protein intake \>1.3 g/kg/day associated with **increased muscle mass**; intake \<1.0 g/kg/day associated with higher risk of muscle mass decline (meta-analysis, SMD 0.75; p \< 0.001)
- At 2.3 g/kg/day, muscle loss was only 0.3 kg vs. 1.6 kg at 1.0 g/kg/day during caloric restriction (Mettler et al.)
- Military personnel consuming 1.6–2.4 g/kg/day preserved anabolic sensitivity during 40% energy deficit vs. lost sensitivity at 0.8 g/kg/day (RDA)

### GLP-1 Direct Effects on Muscle

GLP-1 infusion increased post-meal protein synthetic response by ~62% (vs. ~29% with placebo), potentially due to increased microvascular blood flow (*Aging Cell*).

### Meal Pattern Optimization

- **Per-Meal Target:** 20–30 g protein per feeding session
- **Frequency:** 5+ feeding sessions daily for sustained amino acid supply
- **5–6 small meals** instead of 3 large meals
- **Evening cutoff:** Stop eating 2–3 hours before bedtime
- **Resistance training:** Single most powerful intervention for maintaining lean tissue during weight loss

## Available Agents and Clinical Selection

| Agent | Route | Dosing | Half-Life | CV Benefit | Start → Max |
|----|----|----|----|----|----|
| **Exenatide IR** (Byetta) | SC | BID | 2.4 hr | No | 5 μg → 10 μg BID |
| **Liraglutide** (Victoza) | SC | Daily | 13 hr | **Yes** | 0.6 → 1.8 mg |
| **Dulaglutide** (Trulicity) | SC | Weekly | 5 days | **Yes** | 0.75 → 4.5 mg |
| **Semaglutide SC** (Ozempic) | SC | Weekly | 7 days | **Yes** | 0.25 → 2.0 mg |
| **Semaglutide Oral** (Rybelsus) | Oral | Daily | 7 days | Under study | 3 → 14 mg |
| **Tirzepatide** (Mounjaro) | SC | Weekly | 5 days | Under study | 2.5 → 15 mg |

### Clinical Selection Guide

- **For CV Protection:** Semaglutide SC (strongest signal, 26% MACE reduction), liraglutide (22% CV death reduction), dulaglutide (primary prevention benefit)
- **For Weight Management:** Semaglutide 2.4 mg (Wegovy), tirzepatide (Zepbound, up to 22.5% weight loss)
- **For Convenience:** Weekly agents preferred; oral semaglutide has complex fasting requirements

## Adverse Effects Management

### GI Side Effects (40–85% of patients)

- Typically transient (resolving 4–8 weeks), dose-dependent
- **Nausea Protocol:** Ondansetron 8 mg + metoclopramide 10 mg 30 min before injection reduces nausea from 61.7% to 16.7%
- Avoid strong smells; consume crackers/ginger 30 min post-injection

Endoscopy Warning

Stop GLP-1RA **1 week before upper endoscopy** requiring sedation due to delayed gastric emptying risk.

### Pancreatitis

Real-world study of 161 cases found **no increased recurrent pancreatitis risk**. Prior pancreatitis is not a contraindication to GLP-1RA therapy.

### Hypoglycemia Prevention

- Reduce sulfonylurea dose by 50% when initiating GLP-1RA
- Consider 10–20% basal insulin reduction

### Contraindications

- Personal/family history of medullary thyroid carcinoma
- MEN2 syndrome
- Pregnancy/nursing
- Severe gastroparesis

## Drug Interactions and Combination Therapy

### SGLT2 Inhibitor Combinations

- GLP-1 RAs reduce MACE by 23% (HR 0.77) regardless of baseline SGLT2i use (interaction P = 0.95)
- **Combined additive renal protection:** 38% vs. 21% individual benefit
- **Triple therapy** (SGLT2i + GLP-1RA + nonsteroidal MRA): projected 4.4% ARR with NNT of 23 over 3 years

### RAAS Inhibitor Interactions

- GLP-1RA BP reduction (2–3 mmHg) is additive to ACEi/ARB effects
- No increased hypotension risk based on CVOT safety data (50–94% of participants on RAAS inhibitors)

## Clinical Implementation

### Monitoring Parameters

#### Acute Phase (0–12 weeks)

- Weekly: symptom assessment, weight, glucose patterns
- Biweekly: clinical evaluation during dose escalation

#### Maintenance Phase (\>12 weeks)

- Quarterly: HbA1c (if diabetic), weight, BP
- Semiannually: CMP, lipid profile
- Annually: body composition (DEXA), micronutrient assessment

### Special Populations

- **CKD:** Start lowest dose; benefits demonstrated in CKD stages 3–4; combine with SGLT2i for maximum renal protection
- **HFpEF:** Benefits established (STEP-HFpEF)
- **Elderly (≥75):** Increased dehydration risk; enhanced protein needs (1.2–2.0 g/kg/day)
- **Pregnancy:** Discontinue ≥2 months before conception

## Key References

1.  Perkovic V, et al. Effects of semaglutide on CKD in T2D (FLOW). *N Engl J Med*. 2024;391(2):109–121. [PubMed](https://pubmed.ncbi.nlm.nih.gov/38785209/)
2.  Badve SV, Bilal A, Lee MMY, et al. Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol. 2025;13(1):15-28. [PubMed](https://pubmed.ncbi.nlm.nih.gov/39608381/)
3.  Marso SP, et al. Liraglutide and CV outcomes (LEADER). *N Engl J Med*. 2016;375(4):311–322. [PubMed](https://pubmed.ncbi.nlm.nih.gov/27295427/)
4.  Marso SP, et al. Semaglutide and CV outcomes (SUSTAIN-6). *N Engl J Med*. 2016;375(19):1834–1844. [PubMed](https://pubmed.ncbi.nlm.nih.gov/27633186/)
5.  Gerstein HC, et al. Dulaglutide and CV outcomes (REWIND). *Lancet*. 2019;394:121–130. [PubMed](https://pubmed.ncbi.nlm.nih.gov/31189511/)
6.  Lincoff AM, et al. Semaglutide in obesity without diabetes (SELECT). *N Engl J Med*. 2023;389(24):2221–2232. [PubMed](https://pubmed.ncbi.nlm.nih.gov/37952131/)
7.  Kosiborod MN, et al. Semaglutide in HFpEF with obesity (STEP-HFpEF). *N Engl J Med*. 2023;389(12):1069–1084. [PubMed](https://pubmed.ncbi.nlm.nih.gov/37622681/)
8.  Neuen BL, Heerspink HJL, Vart P, et al. Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria. Circulation. 2024;149(6):450-462. [PubMed](https://pubmed.ncbi.nlm.nih.gov/37952217/)

## Related Mastery Modules

### Also on this topic

The same subject at other levels of depth.

- **Student handout:** [GLP-1 Receptor Agonists for PT Students](https://urinenephrology.org/student-resources/pharmacology/glp1-ra-pt-handout.html)


---

[Website version](https://urinenephrology.org/mastery/cardiorenal/glp1-guide.html) · Markdown synchronized October 3, 2026.